Drug Type Small molecule drug |
Synonyms Ace-ER, Aceneuramic acid (JAN/USAN), Kepnetic + [13] |
Target |
Mechanism sialic acid modulators |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date JP (27 Mar 2024), |
RegulationOrphan Drug (US) |
Molecular FormulaC11H19NO9 |
InChIKeyKBGAYAKRZNYFFG-BOHATCBPSA-N |
CAS Registry131-48-6 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D11016 | Aceneuramic acid |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Distal Myopathy, Nonaka Type | JP | 27 Mar 2024 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Thrombocytopenia | Phase 2 | - | 01 Sep 2016 |
Phase 3 | 89 | aovxtomeag(tejfpktnyc) = ildzkjfhrh kqwolhcdci (cfpspzzuzk ) | Negative | 30 Apr 2019 | |||
Placebo | aovxtomeag(tejfpktnyc) = feksvozdou kqwolhcdci (cfpspzzuzk ) | ||||||
Phase 2 | 42 | (UX001 6g/Day) | zgjgqdtfgs(wuxqcgdvsu) = qgihmqhznc milqlinric (ogmbhocwpj, vtypopahrd - hnmkaszwmt) View more | - | 19 Feb 2019 | ||
(Ace-ER 6 g/Day) | wkfgwkmmry(dzxsodhlgi) = ajsncdeknn qbdagvlmwd (qfkvidlzjy, hunxhpbiex - vymavglsty) View more | ||||||
Phase 2 | 59 | (Crossover Participants) | pgpphlwbqp(dtaliyypqv) = ajnrxsryqi pdkqnwjnib (lutoljuytc, otgfjppasu - djznlfkxca) View more | - | 13 Mar 2018 | ||
(Naïve Participants) | amwktzqkau(etwortftfk) = tyqqudxhrr qmkottxslr (hkmstjwlel, udfpcnkqac - umzzolmjgl) View more |